# A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

> **NCT07641426** · PHASE1,PHASE2 · RECRUITING · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 58 (estimated)

## Conditions studied

- Antibody Mediated Rejection

## Interventions

- **DRUG:** CID-103

## Key facts

- **NCT ID:** NCT07641426
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-09
- **Primary completion:** 2030-05
- **Final completion:** 2030-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641426, "A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07641426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*